In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pint Pharma International S.A.

http://www.pint-pharma.com/

Latest From Pint Pharma International S.A.

BioCryst Says Orladeyo On Slow, Steady Ramp To Blockbuster Sales

Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.

Launches Business Strategies

JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.

Financing Business Strategies

Blue Sky Thinking: CEOs, Analysts Offer Some Thoughts On 2022

As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.

Coronavirus COVID-19 Innovation

FDA Finalizes De Novo Process, Updates Related Guidance Docs

The pathway is used to clear class I and II products that don’t have a predicate device, including many innovative technologies. The original draft rule came out in 2018.

Regulation Review Pathway
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register